---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001695"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:00:04.849125+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology FY2023 revenue $1.78M, net loss $14M, EPS -$3.48

## Summary
- Net loss of ~$14M on total revenue of ~$1.8M for year ended Dec 31, 2023.
- Basic and diluted EPS improved 50% YoY to -$3.48 from -$6.98.
- Cash and cash equivalents $8.7M at Dec 31, 2023, down from $22.1M at Dec 31, 2022.
- Collaboration progress: FluGen intranasal flu vaccine, Cancer Research Horizons glutaminase inhibitors, UPMC ovarian cancer AI study.
- Q4 net loss per share $0.74; company cited cash burn of $13.2M in operating activities.

## SEC filing metadata
- accession: 0001171843-24-001695
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184324001695/0001171843-24-001695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184324001695/f8k_032824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001695
- JSON: https://secwatch.observer/filing/0001171843-24-001695.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001695.txt

## Key facts
- Earnings Releases
  Axe Compute Inc. reported the year ended December 31, 2023 results: revenue approximately $1.8 million, net income approximately $14 million, EPS $3.48 per share.
  - Period: the year ended December 31, 2023
  - Revenue: approximately $1.8 million
  - Net income: approximately $14 million
  - EPS: $3.48 per share
  - Result: reported results
  source text: results for the year ended December 31, 2023, and provided a corporate update. The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023. Q4 2023 and Recent Highlights: Reported meaningful progress with FluGen collaboration designed to bring a first-of-its-kind intranasal flu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446159/000117184324001695/0001171843-24-001695-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.